Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell

Akiyoshi Takami, Shingo Yano, Hiroki Yokoyama, Yachiyo Kuwatsuka, Takuhiro Yamaguchi, Yoshinobu Kanda, Yasuo Morishima, Takahiro Fukuda, Yasushi Miyazaki, Hirohisa Nakamae, Junji Tanaka, Yoshiko Atsuta, Heiwa Kanamori


Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32% ± 4%, 17% ± 3%, and 7% ± 3%, respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients.

Biology of Blood and Marrow Transplantation, In Press, Accepted Manuscript, Available online 14 July 2014
DOI: 10.1016/j.bbmt.2014.07.010


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Search this site

Search form